Upload
noby-ahli-astronom
View
224
Download
0
Embed Size (px)
Citation preview
7/26/2019 Journal Reading Noby
http://slidepdf.com/reader/full/journal-reading-noby 1/24
JOURNAL READING
Oleh : Novita Agustina
(201420401011084)
MENTAL DISORDER DUE TO OPIOID AND ALKOHOL
Supervisor : dr. Iwan Sys, Sp. KJ
SMF ILMU KEDOKTERAN JIWAFAKULTAS KEDOKTERAN
UNIVERSITAS MUHAMMADIYAH MALANG2016
7/26/2019 Journal Reading Noby
http://slidepdf.com/reader/full/journal-reading-noby 2/24
Alcohol Research & Health
Diagnosing Co-Morbid Drug Use in Patients With Alcohol Use
Disorders
Bachaar Arnaout, M.D., and Ismene L. Petrais, M.D. Vol. 31,No. 2, 2008
7/26/2019 Journal Reading Noby
http://slidepdf.com/reader/full/journal-reading-noby 3/24
!omor"idity o# menta$ disorders and su"stance use:A "rie# %uide #or the primary care c$inician
Dru% and A$coho$ Services South Austra$ia &''(
7/26/2019 Journal Reading Noby
http://slidepdf.com/reader/full/journal-reading-noby 4/24
THE PRESCRIPTION OPIOID AND HEROIN
CRISIS: A PUBLIC HEALTH APPROACH TO AN
EPIDEMIC OF ADDICTION
www.annualreviews.org
)uide$ines #or the Psychosocia$$y
Assisted Pharmaco$o%ica$ *reatmento# +pioid Dependence
or$d -ea$th +r%aniation &''/
7/26/2019 Journal Reading Noby
http://slidepdf.com/reader/full/journal-reading-noby 5/24
Pharmacological treatment of mental
disorders in primary health care
World Health Organization 2009
7/26/2019 Journal Reading Noby
http://slidepdf.com/reader/full/journal-reading-noby 6/24
DEFINITION
OPIOIDS (Heroin,codeine,morphine,oxycodone,hydromorphone,
buprenorphine,pethidine,dextropropoxyphene,methadone,tramadol ).
Opioid dependence is characterized by a cluster of cognitive, behavioural and
physiological features. The International Classification of Diseases, 10th edition(ICD-10) identifies six such features:
• a strong desire or sense of compulsion to take opioids
• difficulties in controlling opioid use
• a physiological withdrawal state
• tolerance• progressive neglect of alternative pleasures or interests
because of opioid use
• persisting with opioid use despite clear evidence of overtly
harmful consequences.
7/26/2019 Journal Reading Noby
http://slidepdf.com/reader/full/journal-reading-noby 7/24
Symptoms of dependence include tolerance, withdrawal,
drinking more than intended, giving up social, occupational
or recreational activities because of drinking, and continued
drinking despite knowledge of having a persistent or
recurrent problem.
The depressive effects of alcohol make it a significant risk
factor in the development of mental health problems,
particularly depression. If dependence is established, then
withdrawal effects include nausea and vomiting,agitation,tremor, sweating, hallucinations, and seizures.
7/26/2019 Journal Reading Noby
http://slidepdf.com/reader/full/journal-reading-noby 8/24
EPIDEMIOLOGY
According to the National Survey on Drug Use and Health
(NSDUH), in 2012 about669,000 Americans reported using
heroin. This trend appears to be driven largely by young
adults aged 18–25 among whom there have been the
greatest increases.
7/26/2019 Journal Reading Noby
http://slidepdf.com/reader/full/journal-reading-noby 9/24
Alcohol dependence is common, affecting approximately 6.5%
of men and 1.5% of women. It often develops in early
adulthood, but can start at any age after repeated continued
exposure to alcohol beverages.
The prevalence of alcohol dependence varies in different
countries according to the prevalence and patterns of alcohol
consumption, but in some countries, the 12-month
prevalence of alcohol dependence among adult men is as
high as 10-15%.
In Australia, the 12 month prevalence of harmful use of
alcohol is 3.0% while the prevalence of dependence is 3.5%.
Men are twice as likely to experience dependence compared
with women.
7/26/2019 Journal Reading Noby
http://slidepdf.com/reader/full/journal-reading-noby 10/24
7/26/2019 Journal Reading Noby
http://slidepdf.com/reader/full/journal-reading-noby 11/24
0123+BI+L+)I!AL ASP1!*S +4+PI+ID
D1P10D10!1
The opioid effects of analgesia, euphoria and sedation are
mediated primarily by the mu receptor. Opioids induce
dopamine release indirectly by decreasing gamma-aminobutyric acid (GABA) inhibition. They also induce
dopamine release directly, by interacting with opioid
receptors in the nucleus accumbens.
7/26/2019 Journal Reading Noby
http://slidepdf.com/reader/full/journal-reading-noby 12/24
The effect of chronic opioid exposure on opioid receptor levels has
not been well defined in humans. Tolerance develops throughmultiple mechanisms, including an acute desensitization of the
opioid receptor (which develops within minutes of opioid use and
resolves within hours after use), and a long-term desensitization
of the opioid receptor (which persists for several days after
removal of opioid agonists). Changes also occur in the number ofopioid receptors[25], and there is compensatory up-regulation of
the cyclic adenosine monophosphate (cAMP) producing enzymes.
When the opioid is withdrawn, the cAMP cascade becomes
overactive, leading to the “noradrenergic storm” seen clinically
as opioid withdrawal, which may create a drive to reinstate
substance use. The intensely dysphoric withdrawal syndrome ischaracterized by watery eyes, runny nose, yawning, sweating,
restlessness, irritability, tremor, nausea, vomiting, diarrhoea,
increased blood pressure, chills, cramps and muscles aches; it
can last seven days or even longer.
7/26/2019 Journal Reading Noby
http://slidepdf.com/reader/full/journal-reading-noby 13/24
EFFECTS OF HEROIN USE
7/26/2019 Journal Reading Noby
http://slidepdf.com/reader/full/journal-reading-noby 14/24
7/26/2019 Journal Reading Noby
http://slidepdf.com/reader/full/journal-reading-noby 15/24
7/26/2019 Journal Reading Noby
http://slidepdf.com/reader/full/journal-reading-noby 16/24
TREATMENTS
Three types of medications include:
1. Opioid agonist maintenance treatment,
which activate opioid receptors
2. Partial agonistswhich also activate opioidreceptors but produce a smaller response
3. Antagonists,which block the receptor and
interfere with the rewarding effects of opioids.
7/26/2019 Journal Reading Noby
http://slidepdf.com/reader/full/journal-reading-noby 17/24
TREATMENTS
Oral methadone liquid and sublingual buprenorphine tablets are the medications
most widely used for opioid.
Methadone (Dolophine® or Methadose®) is a slow-acting opioid agonist.
Methadone is taken orally so that it reaches the brain slowly, dampening the
“high” that occurs with other routes of administration while preventing
withdrawal symptoms. The initial methadone dose should be 60-120 mg.
Naltrexone can be useful in preventing relapse in those who have withdrawn from
opioids, particularly in those who are already motivated to abstain from opioid
use. Following opioid withdrawal, patients who are motivated to abstain from
opioid use should be advised to consider naltrexone to prevent relapse.
Buprenorphine (Subutex®) is a partial opioid agonist. Buprenorphine relieves
drug cravings without producing the “high” or dangerous side effects of other
opioids. Suboxone® is a novel formulation of buprenorphine that is taken orally or
sublingually and contains naloxone (an opioid antagonist) to prevent attempts to
get high by injecting the medication.
7/26/2019 Journal Reading Noby
http://slidepdf.com/reader/full/journal-reading-noby 18/24
7/26/2019 Journal Reading Noby
http://slidepdf.com/reader/full/journal-reading-noby 19/24
Psychosocial treatment
Psychosocial interventions including cognitive and
behavioural approaches and contingency management
techniques can add to the effectiveness of treatment, if
combined with agonist maintenance treatment andmedications for assisting opioid withdrawal. Psychosocial
services should be made available to all patients, although
those who do not take up the offer should not be denied
effective pharmacological treatment.
7/26/2019 Journal Reading Noby
http://slidepdf.com/reader/full/journal-reading-noby 20/24
MANAGEMENT
7/26/2019 Journal Reading Noby
http://slidepdf.com/reader/full/journal-reading-noby 21/24
MANAGEMENT
7/26/2019 Journal Reading Noby
http://slidepdf.com/reader/full/journal-reading-noby 22/24
MANAGEMENT
7/26/2019 Journal Reading Noby
http://slidepdf.com/reader/full/journal-reading-noby 23/24
MANAGEMENT
7/26/2019 Journal Reading Noby
http://slidepdf.com/reader/full/journal-reading-noby 24/24
THANK YOU